Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of MK-5890 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03396445
Recruitment Status : Recruiting
First Posted : January 11, 2018
Last Update Posted : February 12, 2021
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : January 27, 2024
Estimated Study Completion Date : January 27, 2024